A new study has revealed that supplementation with Brightseed BioMetaControl could help with glycaemic control in adults with prediabetes.
Brightseed BioMetaControl contains the naturally occurring bioactive compounds N-trans caffeoyltyramine (NCT) and N-trans feruloyltyramine (NFT).
The randomised, double-blind, placebo-controlled clinical trial showed that supplementation with these bioactive compounds significantly improved markers of glycaemic control in adults with prediabetes.
The study was published in the peer-reviewed journal Bioactive Compounds in Health and Disease.
In the four-week trial, 126 adults with prediabetes received either a proprietary sustained-release supplement containing 120 mg/day of NCT/NFT or a placebo.
Participants who received NCT/NFT experienced statistically significant reductions in fasting blood glucose compared to placebo, along with improvements in fasting insulin, postprandial glucose response and reduced time spent outside the ideal glucose range, as measured by continuous glucose monitoring (CGM).
"This study represents one of the first rigorous human clinical trials validating the glucose-regulatory potential of NCT and NFT," said Dr Swati Kalgaonkar, co-author and Head of Medical & Scientific Affairs and Clinical Research at Brightseed.
"By integrating both fasting biomarkers and continuous glucose monitoring, the research provides a more comprehensive picture of how these bioactives support glucose regulation in individuals at risk for metabolic disease.”
NCT and NFT are bioactive compounds found in commercially available edible plants.
The pair were identified through Brightseed’s AI-powered discovery engine based on mechanistic relevance to glucose regulation, biological plausibility and translational potential.
Specifically, the compounds act as potent agonists of hepatocyte nuclear factor 4 alpha (HNF4α), a transcription factor that plays a central role in glucose sensing, insulin secretion and hepatic glucose production.
The study serves as a proof point for a more systematic, AI-driven approach to bioactive discovery — one that connects biological insight, mechanistic reasoning and clinical validation earlier in the innovation process.
While previous research has focused largely on pharmaceutical interventions, these findings highlight the potential role of dietary bioactives as part of a broader lifestyle and nutrition-based approach to metabolic health.
No adverse events related to the study supplement were reported and the intervention was well tolerated.